When Davi D'Agostino was
diagnosed with stage IV pancreatic cancer in early 2018, she didn't let the
odds deter her. She sought out information from reliable sources, advocated for
herself and used her support network to find a treatment plan that worked –
including a clinical trial.
D'Agostino began her treatment with a standard of care chemotherapy. The
treatment was working, but she experienced many strong side effects.
Meanwhile, molecular profiling
revealed that D'Agostino's tumors had a BRCA mutation. After nine rounds of
chemotherapy, D'Agostino enrolled in a clinical trial for patients with this
mutation.
She shared, "PanCAN personnel were excellent and did a narrowed search of
clinical trials, with the knowledge of my BRCA2 tumor mutation and a geographic
parameter I provided. They reduced a hundred possible trials down to 22. The
trial I chose seemed tailor-made for my situation."
On the trial, D'Agostino received access to an investigational targeted therapy
that is working well for her. Though she experienced side effects at first,
they quickly tapered off.
Her primary tumor has stayed stable, and in January 2019, an MRI revealed no
visible or measurable metastases (tumors outside the pancreas). These positive
results continue today.
Contact Patient Central for free information
about clinical trials and molecular profiling, including a personalized
clinical trials search.
No comments:
Post a Comment